Effects of Administration of SCFA in Rheumatoid Arthritis Inadequate Responders

Inclusion Criteria: 1. Diagnosis of RA meeting 2010 ACR/EULAR for RA and/or treating MD diagnosis 2. Inadequate response to MTX per treating MD at maximum tolerated dose. 3. Able and willing to provide written informed consent prior to any study specific procedures 4. Age 18 years and above at time of enrollment 5. Subjects not excluded based on race or ethnicity Exclusion Criteria: 1. Participants who are pregnant or are currently breastfeeding 2. History of sensitivity to study compound or any of their excipients 3. Previous intolerance to SCFA or related compounds 4. Current antibiotic treatment (within 3 months of screening) at discretion of PI 5. Current consumption of probiotics (within 3 months of screening) at discretion of PI 6. Severe hepatic impairment (eg, ascites and/or clinical signs of coagulopathy) 7. Renal failure (eGFR \<30 or requiring dialysis) by history 8. History of other autoimmune disease at discretion of PI 9. Current immunodeficiency state (e.g., cancer, HIV, others)